Hai cercato la traduzione di lyophilisate da Portoghese a Inglese

oral lyophilisate 30, 50, 100 & 200 mg/ ml 39
oral lyophilisate 30,50,100 & 200 mg/ml 39

emea/mb/050/00 relatório anual 2000 page 79/88 medicamento empresa Área terapêutica apresentação emea/cvmp comissão -denom. -nome -espécie -forma -validação -parecer recebido comercial em -dci -origem -indicação -dosagem -parecer -data da decisão -parte a/b -número de -tempo activo -notificação apresentações -tempo inactivo -jornal oficial econor novartis pigs 10%/50% premix -12. 10. 1999 -07. 04. 2000 valnemulin a prevention various -08. 03. 2000 -15. 09. 2000 parte b/treatment of 2 -148 days -22. 09. 2000 (extension) dysentery and -0 -oj c 308, treatment/control of 27. 10. 2000 enzootic pneumonia (qj01xx94) dicural fort cattle pigs solution for injection -16. 12. 1998 -21. 07. 2000 difloxacin dodge antibacterial for 50 mg/ml -21. 06. 2000 -24. 10. 2000 parte b animal systemic use 3 -203 days -25. 10. 2000 (extension) health (qj01ma) -351 days -oj c 337, nl 28. 11. 2000 poulflox virbac poultry oral solution -09. 12. 1999 -21. 07. 2000 difloxacin s. a.antibacterial for 100 mg/ml -21. 06. 2000 -16. 11. 2000 parte b f systemic use 3 -152 days -oj c 2, qj01ma94) -43 days 05. 01. 2001 bayovac csf bayer pigs emulsion for injection -16. 12. 1998 -07. 08. 2000 marker d marker vaccine e2 glycoprotein of -19. 07. 2000 live vaccine against classical classical swine fever -210 days parte a swine fever virus -309 days (qj57ea) 4 porcilis ar-t -intervet pigs suspension for injection -12. 01. 1999 -18. 08. 2000 df internati vaccine against 2 ml -19. 07. 2000 -16. 11. 2000 inactivated onal atrophic rhinitis 2 -204 days -oj c 2, vaccine nl (qj57ea) -336 days 05. 01. 2001 parte a pruban intervet dogs cream -15. 09. 1998 -18. 08. 2000 rescortol internati anti-inflammatory 1 mg/g -19. 07. 2000 -16. 11. 2000 butyrate onal for cutaneous 1 -196 days -oj c 2, parte b nl inflammatory -477 days 05. 01. 2001 disorders (qd07ac90) pirsue pharmaci dairy cattle sterile solution for -12. 01. 1999 -10. 11. 2000 pirlimycin a clinical sub -intramammary use -11. 10. 2000 parte b upojhn clinical mastitis 5 mg/ml -210 days b (qj51ff90) 4 -428 days zubrin schering dogs oral lyophilisate -18. 05. 1999 -08. 12. 2000 tepoxalin -plough treatment of pain 30, 50, 100 200 mg/ml -08. 11. 2000 parte b uk inflammation 39 -210 days -330 days eurican herpes merial dogs powder plus solvent for -13. 07. 1999 -08. 12. 2000 205 f vaccine against emulsion for injection -08. 11. 2000 inactivated canine herpes 1 ml -209 days vaccine 2 -274 days parte bemea/mb/050/00 relatório anual 2000 page 80/88 estabelecimento dos limites máximos de resíduos para substâncias novas substância Área terapêutica emea/cvmp comissão -dci -espécie -validação -enviado à comissão -parecer -data do regulamento -tempo activo -jornal oficial -tempo inactivo bismuth subnitrate bovine -18. 06. 1999 -12. 11. 1999 (extension) -13. 10. 1999 -19. 06. 2000 -113 days -oj l 145, 20. 06. 2000 -0 acetyl isovaleryl porcine -18. 10. 1995 -12. 11. 1999 tylosin tartrate -13. 10. 1999 -19. 06. 2000 -195 days -oj l 145, 20. 06. 2000 -1260 days methylprednisolone bovine -13. 07. 1999 -12. 11. 1999 -13. 10. 1999 -19. 06. 2000 -92 days -oj l 145, 20. 06. 2000 -0 deltamethrin fin fish -09. 12. 1999 -07. 04. 2000 (extension) -08. 03. 2000 -15. 09. 2000 -90 days -oj l 234, 16. 09. 2000 -0 tylosin eggs -09. 11. 1999 -07. 04. 2000 (extension) -08. 03. 2000 -15. 09. 2000 -90 days -oj l 234, 16. 09. 2000 -0 dicyclanil ovine -25. 02. 1997 -07. 04. 2000 -08. 03. 2000 -15. 09. 2000 -281 days -oj l 234, 16. 09. 2000 -825 days tilmicosin rabbit -16. 07. 1999 -12. 11. 1999 (extension) -13. 10. 1999 -20. 10. 2000 -86 days -oj l 269, 21. 10. 2000 -0 flumequine bovine milk turkey -27. 07. 1999 -09. 12. 1999 (extension) -10. 11. 1999 -20. 10. 2000 -89 days -oj l 269, 21. 10. 2000 -0 tiamulin rabbit -14. 10. 1999 -11. 02. 2000 (extension) -12. 01. 2000 -20. 10. 2000 -90 days -oj l 269, 21. 10. 2000 -0 dicyclanil sheep fat -23. 02. 2000 -16. 06. 2000 (modification) -17. 05. 2000 -27. 10. 2000 -84 days -oj l 276, 28. 10. 2000 -0 butafosfan dairy cattle -19. 01. 2000 -19. 05. 2000 (extension) -19. 04. 2000 -27. 10. 2000 -90 days -oj l 276, 28. 10. 2000 -0 tilmicosin bovine milk -22. 02. 1999 -19. 05. 2000 (extension) -19. 04. 2000 -27. 10. 2000 -203 days -oj l 276, 28. 10. 2000 -210 days phoxim ovine -19. 01. 2000 -19. 05. 2000 (extension) -19. 04. 2000 -27. 10. 2000 -90 -oj l 276, 28. 10. 2000 -0 flumethrin ovine -19. 01. 2000 -19. 05. 2000 (extension) -19. 04. 2000 -27. 10. 2000 -90 days -oj l 276, 28. 10. 2000 -0 flunixin equine -23. 03. 2000 -21. 07. 2000 (extension) -21. 06. 2000 -29. 12. 2000 -90 days -oj l 336, 30. 12. 2000 -0emea/mb/050/00 relatório anual 2000 page 81/88 substância Área terapêutica emea/cvmp comissão -dci -espécie -validação -enviado à comissão -parecer -data do regulamento -tempo activo -jornal oficial -tempo inactivo toltrazuril porcine -16. 02. 1999 -21. 07. 2000 (extension) -21. 06. 2000 -29. 12. 2000 -206 days -oj l 336, 30. 12. 2000 -284 days thiamphenicol porcine, ovine, turkey, -15. 05. 1998 -08. 11. 2000 (extension) fish -21. 06. 2000 -206 days -562 days difloxacin bovine, porcine -14. 07. 1998 -21. 07. 2000 (extension) -21. 06. 2000 -29. 12. 2000 -205 days -oj l 336, 30. 12. 2000 -503 days halofuginone bovine -10. 12. 1996 -21. 07. 2000 -21. 06. 2000 -29. 12. 2000 -281 days -oj l 336, 30. 12. 2000 -1008 days linear dodecyl bovine -22. 01. 1999 -18. 08. 2000 benzene sulfonic acid -19. 07. 2000 -195 days -321 days phoxim ovine -19. 01. 2000 -18. 08. 2000 (extension) -19. 07. 2000 -120 days -o acetyl isovaleryl porcine -18. 01. 1995 -18. 02. 2000 tylosin tartrate -13. 09. 2000 -274 days -1790 days florfenicol fish -29. 01. 1996 -08. 11. 2000 (extension) -11. 11. 2000 -212 days -1504 days meloxicam porcine -07. 09. 2000 -04. 01. 2001 (extension) -06. 12. 2000 -90 days -0 days tilmicosin turkey -07. 09. 2000 -04. 01. 2001 z( extension) -06. 12. 2000 -90 days -0 daysemea/mb/050/00 relatório anual 2000 page 82/88 anexo 10 pareceres do comp sobre medicamentos órfãos emitidos em 2000 medicamento patrocinador indicação emea/cpmp comissão -apresentação -parecer recebido em -validação -data da designação -parecer -tempo activo somatropin ares-serono aids-wasting -28. 04. 2000 -17. 07. 2000 (europe) ltd -15. 06. 2000 -08. 08. 2000 -11. 07. 2000 -27 days treatment of fabry disease alpha -tkt europe-5s -03. 05. 2000 -17. 07. 2000 galactosidase a ab -15. 06. 2000 -08. 08. 2000 -11. 07. 2000 -27 days alpha -genzyme bv treatment of fabry disease -12. 05. 2000 -17. 07. 2000 galactosidase a -15. 06. 2000 -08. 08. 2000 -11. 07. 2000 -27 days fluorouracil treatment of glioblastoma ethypharm s. a. -26. 05. 2000 -18. 09. 2000 -31. 07. 2000 -18. 10. 2000 -13. 09. 2000 -45 days gemtuzumab wyeth-ayerst treament of acute myeloid leukaemia -07. 06. 2000 -18. 09. 2000 ozogamicin research -31. 07. 2000 -18. 10. 2000 -13. 09. 2000 -45 days 1, 5 -(butylimino) -oxford treatment of gaucher disease -07. 06. 2000 -18. 09. 2000 1, 5-dideoxy, d -glycosciences -31. 07. 2000 -18. 10. 2000 glucitol ltd -13. 09. 2000 -45 days n-carbamyl-l -orphan europe treatment of n-acetylglutamate synthetase -02. 05. 2000 -18. 09. 2000 glutamic acid sarl (nags) deficiency -31. 07. 2000 -18. 10. 2000 -13. 09. 2000 -45 days arsenic trioxide voisin consulting treatment of acute promyelocytic leukaemia -08. 05. 2000 -18. 09. 2000 sarl -15. 06. 2000 -18. 10. 2000 -13. 09. 2000 -90 days thalidomide laboratoires treatment of erythema nodosum leprosum or -01. 06. 2000 -6. 11. 2000 laphal type ii reactions in hansen" s disease -25. 08. 2000 -29. 12. 2000 -27. 10. 2000 -64 days anagrelide shire treatment of essential thrombocythaemia -31. 05. 2000 -6. 11. 2000 hydrochloride pharmaceutical -31. 07. 2000 -29. 12. 2000 development ltd -27. 10. 2000 -89 days busulfan pierre fabre intravenous conditioning treatment prior to -09. 06. 2000 -6. 11. 2000 (intravenous use) médicament hematopoietic progenitor cell transplantation -31. 07. 2000 -29. 12. 2000 -27. 10. 2000 -89 days nitisinone swedish orphan treatment of tyrosinaemia type 1 -05. 06. 2000 -6. 11. 2000 ab -25. 08. 2000 -29. 12. 2000 -27. 10. 2000 -64 days treatment of huntington" s disease ethyl laxdale ltd -05. 06. 2000 -6. 11. 2000 eicosopentaenoate -31. 07. 2000 -29. 12. 2000 -27. 10. 2000 -89 days iloprost schering ag treatment of primary and of the following -10. 05. 2000 -6. 11. 2000 forms of secondary pulmonary hypertension: -31. 07. 2000 -29. 12. 2000 connective tissue disease pulmonary -27. 10. 2000 hypertension, drug-induced pulmonary -89 days hypertension, portopulmonary hypertension, pulmonary hypertension associated with congenital heart disease and chronic thromboembolic pulmonary hypertension...treatment of amyotrophic lateral sclerosis... -07. 08. 2000 --25. 08. 2000 -21. 11. 2000 -89 days
ovineequineporcineporcine, ovine, turkey, fishbovine, porcinebovinebovineovineporcinefishporcineturkeyemea/cvmp -validation -opinion -active time -clockstop -19.01.2000 -19.04.2000 -90 days -0 -23.03.2000 -21.06.2000 -90 days -0 -16.02.1999 -21.06.2000 -206 days -284 days -15.05.1998 -21.06.2000 -206 days -562 days -14.07.1998 -21.06.2000 -205 days -503 days -10.12.1996 -21.06.2000 -281 days -1008 days -22.01.1999 -19.07.2000 -195 days -321 days -19.01.2000 -19.07.2000 -120 days -0 -18.01.1995 -13.09.2000 -274 days -1790 days -29.01.1996 -11.11.2000 -212 days -1504 days -07.09.2000 -06.12.2000 -90 days -0 days -07.09.2000 -06.12.2000 -90 days -0 dayscommission -sent to commission -date of regulation -official journal-19.05.2000 -27.10.2000 -oj l 276, 28.10.2000-21.07.2000 -29.12.2000 -oj l 336, 30.12.2000-21.07.2000 -29.12.2000 -oj l 336, 30.12.2000-08.11.2000-21.07.2000 -29.12.2000 -oj l 336, 30.12.2000-21.07.2000 -29.12.2000 -oj l 336, 30.12.2000-18.08.2000-18.08.2000-18.02.2000-08.11.2000-04.01.2001-04.01.200181annex 10:comp opinions in 2000 on orphan medicinal productsproductsponsorindicationemea/comp -submission -validation -opinion -active timecommission -opinion received -date of designationsomatropinalpha-galactosidase aalpha-galactosidase afluorouracilgemtuzumab ozogamicin1,5-(butylimino)-1,5-dideoxy, d-glucitoln-carbamyl-l-glutamic acidarsenic trioxideares-serono (europe) ltdtkt europe-5s abgenzyme bvethypharm s. a.wyeth-ayerst researchoxford glycosciences ltdorphan europe sarlvoisin consulting sarlaids-wastingtreatment of fabry diseasetreatment of fabry diseasetreatment of glioblastomatreament of acute myeloid leukaemiatreatment of gaucher diseasetreatment of n-acetylglutamate synthetase (nags) deficiencytreatment of acute promyelocytic leukaemia-28.04.2000 -15.06.2000 -11.07.2000 -27 days-03.05.2000 -15.06.2000 -11.07.2000 -27 days-12.05.2000 -15.06.2000 -11.07.2000 -27 days-26.05.2000 -31.07.2000 -13.09.2000 -45 days-07.06.2000 -31.07.2000 -13.09.2000 -45 days-07.06.2000 -31.07.2000 -13.09.2000 -45 days-02.05.2000 -31.07.2000 -13.09.2000 -45 days-08.05.2000 -15.06.2000 -13.09.2000 -90 days-17.07.2000 -08.08.2000-17.07.2000 -08.08.2000-17.07.2000 -08.08.2000-18.09.2000 -18.10.2000-18.09.2000 -18.10.2000-18.09.2000 -18.10.2000-18.09.2000 -18.10.2000-18.09.2000 -18.10.2000thalidomidelaboratoires laphaltreatment of erythema nodosum leprosum or type ii reactions in hansen 's disease-01.06.2000 -25.08.2000 -27.10.2000 -64 days-6.11.2000 -29.12.200082anagrelide hydrochloridebusulfan (intravenous use)nitisinoneshire pharmaceutical development ltdpierre fabre médicamentswedish orphan abtreatment of essential thrombocythaemiaintravenous conditioning treatment prior to hematopoietic progenitor cell transplantationtreatment of tyrosinaemia type 1-31.05.2000 -31.07.2000 -27.10.2000 -89 days-09.06.2000 -31.07.2000 -27.10.2000 -89 days-05.06.2000 -25.08.2000 -27.10.2000 -64 days-6.11.2000 -29.12.2000-6.11.2000 -29.12.2000-6.11.2000 -29.12.2000emea general report 2000productsponsorindicationemea/comp -submission -validation -opinion -active timecommission -opinion received -date of designationethyl eicosopentaenoateiloprost------------emea general reportlaxdale ltdschering ag------------2000